Traws Pharma (TRAW) Interest Expenses (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Interest Expenses of $266000.0 for Q1 2026, up 15.15% year-over-year from $231000.0 in Q1 2025, and up 212.94% quarter-over-quarter from $85000.0 in Q4 2025.
Traws Pharma (TRAW) Interest Expenses (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Interest Expenses for 13 consecutive years, with $266000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 15.15% year-over-year to $266000.0; the TTM figure through Mar 2026 stood at $266000.0 (up 15.15% YoY), while the FY2025 annual figure was $39.8 million, up 7.94% from the prior year.
- Interest Expenses rose to $266000.0 in Q1 2026 per TRAW's latest filing, from $85000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $170.1 million in Q4 2022 and bottomed at $949.8 in Q3 2023.
- Historically, Interest Expenses has averaged $14.6 million across 5 years, with a median of $193210.5 in 2024.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 99.99% — and 2024, when it surged 168471.91%.
- Traws Pharma's Interest Expenses stood at $170.1 million in 2022, then slumped by 99.99% to $21000.0 in 2023, then jumped by 12747.62% to $2.7 million in 2024, then tumbled by 96.85% to $85000.0 in 2025, then surged by 212.94% to $266000.0 in 2026.
- Business Quant data shows TRAW's Interest Expenses at $266000.0 in Q1 2026, $85000.0 in Q4 2025, and $172000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 266,000.00 |
| Mar 31, 2026 | 266,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Sep 30, 2025 | 172,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Mar 31, 2025 | 231,000.00 |
| Mar 31, 2025 | 231,000.00 |
| Dec 31, 2024 | 2.70 Mn |
| Dec 31, 2024 | 2.70 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 214,421.00 |
| Mar 31, 2024 | 214,421.00 |
| Dec 31, 2023 | 21,000.00 |
| Dec 31, 2023 | 21,000.00 |
| Sep 30, 2023 | 949.80 |
| Sep 30, 2023 | 949.80 |